The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. - Wikidata - wikimedia - TriplyDB

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

http://www.wikidata.org/entity/Q38078480

about

Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer Syndecans as Cell Surface Receptors in Cancer Biology. A Focus on their Interaction with PDZ Domain Proteins Proteoglycans in liver cancer Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine Transmembrane proteoglycans control stretch-activated channels to set cytosolic calcium levels.Syndecan-1 and Its Expanding List of Contacts Insights into the key roles of proteoglycans in breast cancer biology and translational medicine Fibroblast growth factors as tissue repair and regeneration therapeutics.Mechanisms of heparanase inhibitors in cancer therapy.Cancer biology in diabetes.Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice.Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.Heparanase cooperates with Ras to drive breast and skin tumorigenesis Heparanase enhances myeloma progression via CXCL10 downregulation.A liquid chromatography-mass spectrometry-based approach to characterize the substrate specificity of mammalian heparanase.Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme.MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies.Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering.Heparan Sulfate Domains Required for Fibroblast Growth Factor 1 and 2 Signaling through Fibroblast Growth Factor Receptor 1c.Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data.Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection.The potential of heparanase as a therapeutic target in cancer Bioengineered heparins and heparan sulfates.Immunohistochemical expression of heparanase isoforms and syndecan-1 proteins in colorectal adenomas.Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy.Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow.MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.Heparanase augments insulin receptor signaling in breast carcinoma.Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses.The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors Syndecans as modulators and potential pharmacological targets in cancer progression.The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.MicroRNA regulation of proteoglycan function in cancer.

P2860

Q26740617-AA6AC9A0-0D7F-45D9-8EFB-45B01B3D2B3E Q26766484-06385455-B547-4976-AAA3-966C0754155C Q26772304-5927B178-7EFF-435A-8790-B35108245711 Q26777707-8FD2D2ED-77A1-4395-9F8C-3FA1A0F5B5A5 Q26796247-AEB75203-143F-40D9-9257-FF4ABAEF3DF2 Q27310200-C4441FFC-AEAF-414F-AB1B-795EF8E82115 Q28084514-AC7901F5-02AC-4C23-B003-2196BAAC2210 Q28085548-9280F166-5E5A-499A-9CDA-351963F738DD Q28272364-A02F53C8-A9B9-4E7E-91C6-D3E363DFD709 Q30244089-B5ED8D68-4C45-4781-9682-2233F16AB8F6 Q33608038-28B6A24B-91F3-4FE9-9998-62237209501D Q33761544-EE636EDE-A504-41F7-916C-F69EE0926921 Q34039967-4D0BBF8B-84AA-4B64-8E1F-974E19FF1DC8 Q34052534-F25D0F4F-1289-4BF9-B5B8-5BC146FCDCE2 Q34289445-FC667AB0-2DC8-40AC-8C56-26480D32D475 Q34634250-7DD6C0B7-2D12-4D3F-AEAF-637B9FFC2C69 Q35078198-691610C3-3453-4397-B7C8-BC53DF7669C5 Q35102577-53F8E76E-AF89-48A1-95A3-B7C1CD587754 Q35145657-9A0CD536-E2C9-4CD6-A15B-67AA9F2F4DE1 Q35470322-C89D6F93-84AF-45A9-879C-D0639E90DE54 Q35830856-CFC84143-FA25-475E-B4FB-E641AA237B36 Q35987516-AB03647D-115D-46D0-AC92-171DEBFF95B6 Q36235128-30A0511E-BB26-4593-8675-38539F990DEB Q36339725-D529412F-D7B8-4C41-B332-328302210BB7 Q36376623-A6D0D99E-BA6F-4457-94DC-2669264AFE01 Q36452903-C9848EE1-1DB8-496B-8594-5BF40F0469C4 Q36578686-F9159E26-7F42-41A4-8243-B2663509DF65 Q36707619-D9F09CAC-11A4-49D2-A910-D33057C23A63 Q36853911-C5E6D653-734E-4884-9024-388C6BEA8B50 Q37282934-1C963D86-42A1-465A-9B08-D9D6DCFC711C Q37499263-A8182F11-2003-4D2C-8AF8-A2C8E694D6BD Q37535244-C032E718-2812-440B-9B1C-B0C3F79A51FD Q37683359-66C3FFF4-35C0-4956-B134-CE254058A344 Q37688166-C435C9A8-D39F-4AD0-8756-04B7358281DC Q37746011-48D759D7-D9A6-4C84-825B-54EAEE607FD4 Q38116039-396BEFA2-03F9-4CF9-B0B4-31CB6EBD31E6 Q38176008-67143C8E-5866-4644-84E2-B4B4F777AA7D Q38189392-B1D307A9-F16F-4407-B4C7-913895185446 Q38238094-3AC2788D-EF30-4D26-B186-E6059015224C Q38244283-2BBC7BCA-F310-4A8F-AF48-00A89C9B5179

P2860

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

http://www.wikidata.org/entity/Q38078480

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

@en

type

label

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

@en

prefLabel

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

@en

P1433

Q38078480-8793810B-499B-4424-A61D-D25F8C9B98CE

P1476

Q38078480-59C8860B-2EB2-499E-ADBB-77DB973B1EC2

P2093

Q38078480-083D3DF1-307B-4DF9-BA94-7EBE87EBEF6C

Q38078480-1CAB94D8-3585-4A14-83E8-0BC0AC4BA4C0

Q38078480-439D8C25-05B6-47A3-8B5C-6B37F49F26E9

Q38078480-64D810E2-FB6B-4956-AF2C-4F1A46D6526A

Q38078480-6E05C616-5D70-4AC4-A2F8-8B6BEE3E10A4

Q38078480-9304ABB6-50BF-4C27-B25E-E0AD720E491A

Q38078480-A8A3422C-78FC-4053-AAE1-B4B32BCBF84D

P2860

Q38078480-00169962-CAEF-49B9-B796-D1052D366481

Q38078480-02135FCC-07F7-45AB-BF54-89C661650E4D

Q38078480-024A768C-164D-45DE-BAF2-7C2869F483A9

Q38078480-04F0D914-F46F-4C8C-A0DB-B7895A583E36

Q38078480-0735EB7B-7B1B-4735-8127-E346AC2ACCE2

Q38078480-07CFAAB1-9D51-49F0-8FB5-A85E125FA530

Q38078480-08AC30CD-5569-4CB2-91DC-AAC34F46C46A

Q38078480-09BF05C6-3F25-488C-AF6B-1BC9BDE44293

Q38078480-10C80B6B-FE1D-4739-934F-FAF099C31BF5

Q38078480-18FC1CCD-16A8-41B0-9FF4-31FCF6F41BF6

P304

Q38078480-AA09E9FC-397A-4204-B404-91E47A8D79FB

P31

Q38078480-9A29188C-C52D-4CD3-B700-1229153B8008

P356

Q38078480-D6F95115-59AF-494F-A4D6-889968A65507

P407

Q38078480-D2540F86-F625-4DA3-99EE-A0A7360F223C

P433

Q38078480-747D4F0F-0E8F-498C-B2E6-6B2D98EBB604

P478

Q38078480-D7ADBE02-528A-4F58-9C04-405E81047AF3

P577

Q38078480-9DB1BE15-D845-438B-91A0-A5054E0CDE0F

P5875

Q38078480-69F38767-CBB6-4463-9548-2DD26487B610

P698

Q38078480-24F90C21-E12A-4763-A8C7-8FF35434DB56

P932

Q38078480-E73A957B-35D7-4FD6-9DCA-6EA392196C7E

P356

P1433

P1476

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

@en

P2093

Anurag Purushothaman

http://www.w3.org/2001/XMLSchema#string

Camilla A Thompson

http://www.w3.org/2001/XMLSchema#string

Israel Vlodavsky

http://www.w3.org/2001/XMLSchema#string

Jessie L-S Au

http://www.w3.org/2001/XMLSchema#string

Mark D Stewart

http://www.w3.org/2001/XMLSchema#string

Ralph D Sanderson

http://www.w3.org/2001/XMLSchema#string

Vishnu C Ramani

http://www.w3.org/2001/XMLSchema#string

P2860

Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin.

Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT)

Large-scale proteomics and phosphoproteomics of urinary exosomes

Syndecan-syntenin-ALIX regulates the biogenesis of exosomes

Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans

PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

Met, metastasis, motility and more

P304

2294-2306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/FEBS.12168

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

280

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235394562

http://www.w3.org/2001/XMLSchema#string

P698

23374281

http://www.w3.org/2001/XMLSchema#string

P932

3651779

http://www.w3.org/2001/XMLSchema#string